Table of Contents
Do not index
Biotech executives ask this question in some variation on almost every introductory conversation: "How do I explain what we do on LinkedIn without losing people in the science, but without dumbing it down so much that I lose credibility with the people who actually matter?" It is the right question, and the answer is more direct than most LinkedIn advice will tell you. The executives who build the strongest presence in this space do not lead with the science at all. They lead with the human stakes. Investors, partners, and talent need to believe in the person before they commit to the pipeline. When your profile and posts make the why of your research legible to someone outside your field, the credibility with those inside it follows automatically.
Why Human Stakes Come Before the Science
Consider what actually happens when a Series B investor, a potential chief medical officer, or a biotech-adjacent BD executive lands on your LinkedIn profile. They are not evaluating your mechanism of action. They are evaluating whether you are someone worth a two-hour conversation. They are reading for conviction, clarity, and the kind of judgment that only comes from someone who has lived close to the problem. If your headline is a job title and your About section is a paragraph of technical nomenclature, they have no entry point. They move on. The science is not the problem. The absence of a human being behind the science is.
This is where most biotech executives get the positioning backwards. They assume that leading with technical depth signals seriousness. What it actually signals is an inability to communicate outside the lab, which is a liability for anyone who needs to raise capital, recruit exceptional people, or close partnership agreements. The executives who attract the right attention on LinkedIn are not the ones with the most impressive publications list. They are the ones who can make a non-scientist understand why the work matters, and do it in two sentences.
The mechanism here is not about simplification. It is about sequencing. You are not replacing the science with something softer. You are leading with the reason the science exists, so that when you do go deep, your audience is already oriented. A post about why a specific patient population has been ignored by existing treatments for thirty years does more positioning work than a post explaining your novel protein degradation approach, even though the second post demonstrates more technical knowledge. The first post earns the reader. The second post rewards them.
The Human-First Sequencing Framework
What I call the Human-First Sequencing Framework is not a content formula. It is a positioning logic that governs every decision on your profile and in your posts. The framework has three moves, applied in order. First, establish the human cost of the problem your research addresses, with enough specificity that a non-scientist can feel the weight of it. Second, position yourself as someone who has been close to that problem long enough to understand something others have missed. Third, let the science serve as evidence of the first two, not as the lead.
Applied to your LinkedIn profile, this means your headline does not say "CEO | Oncology Drug Development | Series A Biotech." It says something closer to what you would say at a dinner table when someone asks what you actually do and why. Your About section opens with the moment you understood the problem was real, not with a summary of your credentials. Your posts document the decisions you make and the reasoning behind them, not the milestones you hit. The distinction matters because milestones are about the company. Decisions are about you. And what investors, partners, and talent are evaluating is you.
This is the same logic that applies to any expert building a LinkedIn presence around complex, high-stakes work. Business consultants who document specific problems they have solved, with enough detail that readers recognize their own situation, build the kind of credibility that makes the sales conversation feel like a formality — the goal is never to explain what you do, but to demonstrate that you understand the problem better than anyone else in the room. The same principle governs biotech executive positioning, with higher stakes and a more specialized audience.
Who This Is For and Who It Is Not
This framework is built for biotech executives who are actively in market — raising a round, recruiting leadership, building partnership pipelines, or establishing the kind of profile that makes inbound introductions possible. If you are running a two-to-five person team in pre-clinical or early clinical stages, or if you are a founder-CEO who needs to be the face of the company because the company does not yet have the track record to speak for itself, this applies directly to you. The same applies if you are a CSO or CBO at a company doing $5M to $50M in annual revenue who needs to build a personal presence independent of the company brand.
This does not work if you are looking for a shortcut to visibility without the underlying conviction. The Human-First Sequencing Framework requires that you actually have a perspective on the problem your company is solving, not just a technical grasp of the solution. If your relationship to the work is purely scientific and you have no genuine answer to why this patient population, why now, why you, then no amount of LinkedIn strategy will substitute for that. Skip this if you are hoping that consistent posting will compensate for unclear positioning. It will not. What you post is downstream of what you believe, and audiences at the level you are trying to reach can tell the difference.
This also does not apply to executives who are primarily building a profile for board recruitment or for internal credibility within an established organization. Those are different objectives with different mechanics, and conflating them with investor-facing or talent-facing positioning is one of the more expensive mistakes I see at this level.
What This Means for Your Trajectory
The compounding effect of human-first positioning is not immediate, but it is durable in a way that technical credibility alone is not. When your LinkedIn presence makes the stakes of your work legible to someone outside your field, you stop being filtered out of conversations before they start. Investors who do not yet understand your science begin to trust your judgment. Potential hires who are evaluating five opportunities begin to feel the pull of your specific mission. Partners who are assessing fit begin to see you as someone who thinks clearly under pressure, not just someone with an impressive CV.
The executives who understand this early build networks that work without active management. Their posts get shared by people who cannot fully evaluate the science but can fully evaluate the conviction. Their profiles generate introductions from unexpected directions. The pipeline of relationships that makes fundraising, hiring, and partnership development easier is not built by posting more frequently or optimizing your headline for search terms. It is built by making the human case for your work so clearly that the right people feel compelled to be part of it. That is what LinkedIn presence actually does at this level, and it starts with leading with the why before you ever mention the how.
